Clinical trial
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in…
NCT04960202 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT04960202 |
|---|---|
| Title | EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 |
| Official title | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | COVID-19 |
| Intervention type | Drug |
| Interventions | PF-07321332, Ritonavir, Placebo |
| Enrollment | 2,091 |
| Start date | Jul 16, 2021 |
| Primary completion | Dec 9, 2021 |
| Completion | Apr 25, 2022 |
| First posted | Jul 13, 2021 |
| Last update posted | Jul 10, 2025 |
| Countries | Argentina, Brazil, Bulgaria, Colombia, Czechia, Hungary, India, Japan, Malaysia, Mexico, Poland, Puerto Rico and 8 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: